-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 17.3% in December
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 17.3% in December
Biofrontera Inc. (NASDAQ:BFRI – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 467,400 shares, a growth of 17.3% from the December 15th total of 398,500 shares. Based on an average daily trading volume, of 107,900 shares, the short-interest ratio is presently 4.3 days. Approximately 3.7% of the company's stock are short sold.
Institutional Trading of Biofrontera
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp purchased a new stake in shares of Biofrontera during the second quarter worth about $39,000. State Street Corp grew its holdings in Biofrontera by 55.8% in the second quarter. State Street Corp now owns 22,900 shares of the company's stock valued at $43,000 after purchasing an additional 8,200 shares during the period. XTX Topco Ltd purchased a new stake in Biofrontera in the first quarter valued at approximately $48,000. BlackRock Inc. grew its holdings in Biofrontera by 894.0% in the first quarter. BlackRock Inc. now owns 100,505 shares of the company's stock valued at $335,000 after purchasing an additional 90,394 shares during the period. Finally, Bard Associates Inc. grew its holdings in Biofrontera by 5.4% in the second quarter. Bard Associates Inc. now owns 259,275 shares of the company's stock valued at $482,000 after purchasing an additional 13,200 shares during the period. Institutional investors and hedge funds own 6.84% of the company's stock.
Get Biofrontera alerts:Biofrontera Stock Performance
BFRI stock opened at $0.91 on Friday. The company's 50 day moving average price is $0.95 and its 200 day moving average price is $1.16. Biofrontera has a fifty-two week low of $0.75 and a fifty-two week high of $6.12. The firm has a market capitalization of $24.39 million, a price-to-earnings ratio of -0.81 and a beta of 1.12.
Biofrontera (NASDAQ:BFRI – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09. Biofrontera had a negative net margin of 44.62% and a negative return on equity of 113.65%. The firm had revenue of $4.32 million for the quarter, compared to analyst estimates of $4.32 million. Equities analysts forecast that Biofrontera will post -0.98 EPS for the current fiscal year.Biofrontera Company Profile
(Get Rating)
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Featured Stories
- Get a free copy of the StockNews.com research report on Biofrontera (BFRI)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
纳斯达克公司(BFRI-GET Rating)是12月份空头股数业务大幅增长的接收方。截至12月30日,空头股数共有467,400股,较12月15日的398,500股增长17.3%。以日均成交量十七万七千九百股计算,目前短息比率为四点三天。该公司约3.7%的股票被卖空。
生物前翅目昆虫的制度性交易
对冲基金和其他机构投资者最近改变了他们在该股的头寸。北方信托公司在第二季度购买了Biofrontera的新股份,价值约3.9万美元。道富集团第二季度持有的Biofrontera股份增加了55.8%。道富集团目前持有22,900股该公司股票,价值43,000美元,在此期间又购买了8,200股。XTX Topco Ltd在第一季度购买了Biofrontera的新股份,价值约为48,000美元。贝莱德股份有限公司第一季度增持了894.0%的Biofrontera股份。贝莱德股份有限公司在此期间增持了90,394股,目前持有100,505股该公司股票,价值335,000美元。最后,Bard Associates Inc.在第二季度增持了Biofrontera 5.4%的股份。Bard Associates Inc.目前持有259,275股该公司股票,价值482,000美元,在此期间又购买了13,200股。机构投资者和对冲基金持有该公司6.84%的股票。
到达生物翅目警报:Biofrontera股票表现
上周五,BFRI股价开盘报0.91美元。该公司的50日移动均线价格为0.95美元,其200日移动均线价格为1.16美元。Biofrontera的52周低点为0.75美元,52周高位为6.12美元。该公司的市值为2439万美元,市盈率为-0.81倍,贝塔系数为1.12。
纳斯达克(BFRI-GET Rating)上一次发布收益报告是在11月14日(星期一)。该公司公布本季度每股收益(0.23美元),比分析师普遍预期的(0.32美元)高出0.09美元。Biofrontera的净利润率为负44.62%,净资产回报率为负113.65%。该公司本季度营收为432万美元,而分析师预期为432万美元。股票分析师预测,Biofrontera本财年的每股收益将达到0.98%。Biofrontera公司简介
(获取评级)
Biofrontera Inc是一家生物制药公司,在美国从事治疗皮肤病的药物产品的商业化。该公司提供处方药Ameluz和用于光动力疗法的RhodoLED灯系列,用于面部和头皮轻至中度光化性角化病的病变导向和视野导向治疗。
专题报道
- 免费获取StockNews.com关于生物前翅目(BFRI)的研究报告
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
接受《Biofrontera Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Biofrontera和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧